HC Wainwright & Co. Maintains Buy on Cerevel Therapeutics Hldg, Lowers Price Target to $41
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Cerevel Therapeutics Hldg (NASDAQ:CERE) but lowers the price target from $45 to $41.
August 04, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Cerevel Therapeutics, indicating continued confidence in the company's prospects.
The lowered price target might initially cause some negative sentiment among investors. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any short-term negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100